Literature DB >> 3510531

Adriamycin-induced glomerulosclerosis in the rat.

T Bertani, G Rocchi, G Sacchi, G Mecca, G Remuzzi.   

Abstract

To evaluate long-term effect of sustained proteinuria induced by a single injection of adriamycin (ADR) on occurrence of focal segmental glomerulosclerosis (FSG), we treated 50 Sprague-Dawley (SD) rats, weighing 250 g with 5 mg/kg body weight of ADR. After six months of heavy proteinuria, 40% of ADR-treated rats did not develop FSG. In the remaining 60% of animals, a mild FSG was observed associated with the presence of large tubular casts and interstitial inflammation. Glomerulosclerosis was never observed in absence of tubulointerstitial lesions. Nine months after ADR, all rats exhibited FSG with renal insufficiency but the severest changes were restricted to the tubulointerstitial level. Our results indicate that chronic proteinuria induced by ADR is a relatively good model of glomerular sclerosis, however, the cause of glomerular sclerosis is probably different from that operating in other experimental models of FSG. Both sclerotic changes and progression of disease seem to be dependent on formation of tubular casts with consequent interstitial changes. This study raises the question of the relative role of tubulointerstitial changes in the subsequent development of FSG.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3510531     DOI: 10.1016/s0272-6386(86)80051-8

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  12 in total

1.  Regulation of innate immunity by the nucleotide pathway in children with idiopathic nephrotic syndrome.

Authors:  R Bertelli; M Bodria; M Nobile; S Alloisio; R Barbieri; G Montobbio; P Patrone; G M Ghiggeri
Journal:  Clin Exp Immunol       Date:  2011-07-15       Impact factor: 4.330

2.  Thirst and sodium appetite in rats with experimental nephrotic syndrome.

Authors:  Jie Xu; Alan Kim Johnson; Robert L Thunhorst
Journal:  Physiol Behav       Date:  2015-06-26

3.  Interstitial nephritis induced by protein-overload proteinuria.

Authors:  A A Eddy
Journal:  Am J Pathol       Date:  1989-10       Impact factor: 4.307

4.  Failure of regulation results in an amplified oxidation burst by neutrophils in children with primary nephrotic syndrome.

Authors:  R Bertelli; A Trivelli; A Magnasco; M Cioni; M Bodria; A Carrea; G Montobbio; G Barbano; G M Ghiggeri
Journal:  Clin Exp Immunol       Date:  2010-05-19       Impact factor: 4.330

5.  A relationship between proteinuria and acute tubulointerstitial disease in rats with experimental nephrotic syndrome.

Authors:  A A Eddy; L McCulloch; E Liu; J Adams
Journal:  Am J Pathol       Date:  1991-05       Impact factor: 4.307

6.  A Mendelian locus on chromosome 16 determines susceptibility to doxorubicin nephropathy in the mouse.

Authors:  Zongyu Zheng; Kai M Schmidt-Ott; Streamson Chua; Kirk A Foster; Rachelle Z Frankel; Paul Pavlidis; Jonathan Barasch; Vivette D D'Agati; Ali G Gharavi
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-07       Impact factor: 11.205

Review 7.  Recent advances of animal model of focal segmental glomerulosclerosis.

Authors:  Jae Won Yang; Anne Katrin Dettmar; Andreas Kronbichler; Heon Yung Gee; Moin Saleem; Seong Heon Kim; Jae Il Shin
Journal:  Clin Exp Nephrol       Date:  2018-03-20       Impact factor: 2.801

8.  IL-1-like production in adriamycin-induced nephrotic syndrome in the rat.

Authors:  T Bricio; A Molina; J Egido; E Gonzalez; F Mampaso
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

Review 9.  The role of platelet-activating factor (PAF) in experimental glomerular injury.

Authors:  A Ortiz; M Gomez-Chiarri; J L Lerma; E Gonzalez; J Egido
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

Review 10.  Pathophysiology and treatment of focal segmental glomerulosclerosis: the role of animal models.

Authors:  Sylvana M L de Mik; Martin J Hoogduijn; Ron W de Bruin; Frank J M F Dor
Journal:  BMC Nephrol       Date:  2013-04-01       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.